PSMA-Targeted PET Imaging and Radioligand Therapy in the Management of Prostate Cancer: What Urologists Need to Know

Registration / Breakfast: 7:30 – 8am
Symposium: 8 – 9:30 am

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is highly expressed by prostate cancer cells. In recent years, two small molecules targeting PSMA agents (68Ga-PSMA-11 and 18F-DCFPyL) have been approved by the U.S. Food and Drug Administration for imaging men with localized high-risk or recurrent prostate cancer using positron emission tomography (PET). Additionally, a beta-particle emitting radiotherapeutic agent targeting PSMA (177Lu-PSMA-617) has been approved for the treatment of men with castration-resistant prostate cancer.

In this session, co-presented by a nuclear radiologist and a urologist, we will discuss the basic principles of PET imaging and review the results from key trials of PSMA-targeted PET imaging. We will describe important clinical scenarios in which PSMA-targeted PET imaging is indicated, with a focus on initial cancer staging, biochemical recurrence, management of oligometastatic disease, and selection of candidates for PSMA-targeted radioligand therapy. Additionally, we will review how one can start programs in PSMA-targeted PET imaging and radioligand therapy. Attendees should be able to return to their practices with the knowledge necessary to start ordering PSMA PET scans and to discuss test results with patients. Additionally, urologists should be able to discuss radioligand therapy with their patients and where this novel therapy fits in the current treatment paradigm for men with castration-resistant prostate cancer. We hope this is a highly interactive session and strongly encourage participation from the audience.

CME Credit Designation: Participants will be eligible to receive 1.5 AMA-PRA Category 1 Credits and a certificate of participation from the Society of Nuclear Medicine and Molecular Imaging.

Register here: www.snmmi.org/2023psmasymposium